Table 1

First subsequent anticancer therapy among patients who discontinued tebentafusp

Type of anticancer therapy, n (%)Overall (N=146)Best overall response to first subsequent therapy, n (%)
CRPRSDPDNE/missing
Any therapy88 (60)1 (1)3 (3)34 (39)21 (24)29 (33)
 Systemic65 (74)1 (2)2 (3)16 (25)21 (32)25 (38)
 Immunotherapy54 (61)1 (2)2 (4)14 (26)16 (30)21 (39)
 Anti-CTLA4 monotherapy5 (6)002 (40)2 (40)1 (20)
 Anti-PD1/PDL1 monotherapy19 (22)007 (37)6 (32)6 (32)
 Anti-PD1+anti-CTLA428 (32)1 (4)2 (7)4 (14)7 (25)14 (50)
 Chemotherapy4 (5)0001 (25)3 (75)
 Targeted therapy8 (9)002 (25)5 (63)1 (13)
 Local34 (39)01 (3)22 (65)2 (6)9 (26)
 Radiotherapy12 (14)01 (8)6 (50)05 (42)
 Liver-directed therapy22 (25)0016 (73)2 (9)4 (18)
  • Patients could have received more than one subsequent therapy.

  • CR, complete response; CTLA4, cytotoxic T lymphocyte-associated protein 4; NE, not evaluable; PD, progressive disease; PD-1, programmed death 1; PD-L1, programmed death ligand 1; PR, partial response; SD, stable disease.